Why did my CRBP drop?
Corbus Pharmaceuticals' (Nasdaq: CRBP) shares have dropped precipitously on the news that its drug lenabasum has failed to effectively treat the inflammatory disease dermatomyositis in a late-stage clinical trial.
Will CRBP stock recover?
On average, Wall Street analysts predict that Corbus Pharmaceuticals Holdings's share price could reach $1.98 by May 12, 2023. The average Corbus Pharmaceuticals Holdings stock price prediction forecasts a potential upside of 685.71% from the current CRBP share price of $0.25.
What is going on with corbus pharmaceuticals?
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates. Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022.
Should I sell CRBP stock?
The consensus among Wall Street equities research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
What is Lenabasum?
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2). It resolves inflammation and limits fibrosis.
Will corbus stock go back up?
The 1 analysts offering 12-month price forecasts for Corbus Pharmaceuticals Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +1,039.38% increase from the last price of 0.26.
Should I buy corbus pharmaceuticals?
Corbus Pharmaceuticals has 934.48% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
Where is corbus Pharmaceuticals located?
Norwood, MassachusettsCorbus is based in Norwood, Massachusetts.
What is the CRBP mAb?
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β (TGFβ). TGFβ is a multifunctional cytokine involved in many cellular processes, including cell growth and differentiation, immune responses, wound healing, and tissue repair. CRB-601 is an anti- α vβ8 mAb expressed by cancer cells. Corbus plans to develop CRB-601 to treat solid t
When will Corbus have four compounds?
With these additions, Corbus expects to have four compounds other than lenabasum in Phase 1 testing in 2022.
When will Corbus study phase 1?
Corbus believes targeting both integrins at once is a rational approach to treating fibrotic diseases and carcinomas. Phase 1 studies are expected to start in 2022.
A late-stage clinical failure is weighing heavily on the biotech's stock today
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
What happened
Shares of the clinical-stage biotech Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) fell by as much as 77% in pre-market trading Tuesday morning. The drugmaker's shares are tanking this morning in response to a negative late-stage readout for lenabasum in patients with a rare autoimmune disorder known as diffuse cutaneous systemic sclerosis (SSc).
So what
Lenabasum stood to become the first ever FDA-approved treatment for SSc. Corbus, in turn, would have more than likely had a blockbuster drug on its hands if the drug had passed this critical test.
Now what
Should bargain hunters pounce on this biotech stock today? Lenabasum may ultimately redeem itself in another high-value indication. Corbus, after all, isn't that far off from releasing the drug's top-line results in cystic fibrosis. That's the good news.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
CRBP POWR Grades
CRBP scores best on the Value dimension, with a Value rank ahead of 52.41% of US stocks.
CRBP Stock Summary
As for revenue growth, note that CRBP's revenue has grown -73.69% over the past 12 months; that beats the revenue growth of just 2.25% of US companies in our set.
CRBP Valuation Summary
In comparison to the median Healthcare stock, CRBP's price/sales ratio is 432.16% higher, now standing at 60.4.
CRBP Growth Metrics
Its 3 year net income to common stockholders growth rate is now at -587.86%.
CRBP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Latest CRBP News From Around the Web
Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.
